U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H20N2
Molecular Weight 264.3655
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MIANSERIN

SMILES

CN1CCN2c3ccccc3Cc4ccccc4C2C1

InChI

InChIKey=UEQUQVLFIPOEMF-UHFFFAOYSA-N
InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3

HIDE SMILES / InChI

Molecular Formula C18H20N2
Molecular Weight 264.3655
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15771415 | http://www.medicines.org.au/files/mkptolvo.pdf

Mianserin is a tetracyclic antidepressant used for the treatment of depression. It was investigated as an adjuvant for reduction of negative and cognitive symptoms of schizophrenia, as an aid for opioid detoxification therapy (where it reduced symptoms but lead to higher drop-out rate), and for the treatment of post-traumatic stress disorder (where it was ineffective). Mianserin has a broad spectrum of activity with the most potent binding to 5-HT2A, 5-HT2C, H1, alpha2A and alpha2C receptor.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TOVLON

Approved Use

For the treatment of major depression.
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Meta-analytical studies on new antidepressants.
2001
Effects of mirtazapine on the levels of exogenous histamine in the plasma of the cat.
2001
Availability of learned helplessness test as a model of depression compared to a forced swimming test in rats.
2001
Mirtazapine and bone marrow suppression: a case report.
2001 Aug
m-CPP hypolocomotion is selectively antagonized by compounds with high affinity for 5-HT(2C) receptors but not 5-HT(2A) or 5-HT(2B) receptors.
2001 Dec
First report of mirtazapine-induced arthralgia.
2001 Dec
Relative safety of mirtazapine overdose.
2001 Dec
Altered dendritic spine density in animal models of depression and in response to antidepressant treatment.
2001 Dec 1
Effects of voluntary ethanol intake on the expression of Ca(2+) /calmodulin-dependent protein kinase IV and on CREB expression and phosphorylation in the rat nucleus accumbens.
2001 Dec 21
A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders.
2001 Fall
A review of the pharmacological and clinical profile of mirtazapine.
2001 Fall
[Postoperative pain syndrome and its relationship with individual psychological features of personality].
2001 Jul-Aug
Effect of antidepressants on ATP-dependent calcium uptake by neuronal endoplasmic reticulum.
2001 Nov
Peripheral edema associated with mirtazapine.
2001 Nov
The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period.
2001 Nov
[Interference in the serotoninergic and noradrenergic system. Faster out of depression].
2001 Nov 1
Trait anxiety and the effect of a single high dose of diazepam in unipolar depression.
2001 Nov-Dec
Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients.
2001 Oct
Fluvoxamine augmentation increases serum mirtazapine concentrations three- to fourfold.
2001 Oct
Serotonin syndrome induced by fluvoxamine and mirtazapine.
2001 Oct
Prevention of the stress-induced increase in frontal cortical dopamine efflux of freely moving rats by long-term treatment with antidepressant drugs.
2001 Oct
Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells.
2001 Oct
Mirtazapine versus fluoxetine in the treatment of panic disorder.
2001 Oct
Mirtazapine treatment of obsessive-compulsive disorder.
2001 Oct
Treatment of mood-congruent psychotic depression with imipramine.
2001 Oct
Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor.
2001 Oct
Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy.
2001 Sep
Mirtazapine for treatment of depression and comorbidities in Alzheimer disease.
2001 Sep
[Toxicological analysis in the dawn of the third millenium].
2001 Sep-Oct
Decreased [(3)H]spiperone binding in the anterior cingulate cortex of schizophrenia patients: an autoradiographic study.
2002
Mirtazapine overdose with benign outcome.
2002 Apr
PET evaluation of a tetracyclic, atypical antidepressant, [N-methyl-11C]mianserin, in the living porcine brain.
2002 Apr
Serotonin syndrome and atypical antipsychotics.
2002 Apr
Severe serotonin syndrome induced by mirtazapine monotherapy.
2002 Apr
Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents.
2002 Apr
In the rat forced swimming test, NA-system mediated interactions may prevent the 5-HT properties of some subacute antidepressant treatments being expressed.
2002 Apr
Spectrophotometric, spectrofluorimetric, HPLC and CZE determination of mirtazapine in pharmaceutical tablets.
2002 Apr 15
[Unexpected drug-interaction].
2002 Feb
Imipramine, mianserine and maprotiline block delayed rectifier potassium current in ventricular myocytes.
2002 Feb
Intravenous mirtazapine in the treatment of depressed inpatients.
2002 Feb
Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects--a possible opioid involvement in severe depression?
2002 Feb-Apr
Chronic treatment with imipramine or mirtazapine antagonizes stress- and FG7142-induced increase in cortical norepinephrine output in freely moving rats.
2002 Jan
Mirtazapine, but not fluvoxamine, normalizes the blunted REM sleep response to clonidine in depressed patients: implications for subsensitivity of alpha(2)-adrenergic receptors in depression.
2002 Jan 31
Successful treatment of recurrent brief depression with reboxetine -- a single case analysis.
2002 Mar
Effect of repeated treatment with mirtazapine on the central alpha1-adrenergic receptors.
2002 Mar
Heart rate variability as predictor of nonresponse to mirtazapine in panic disorder: a preliminary study.
2002 Mar
Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia.
2002 Mar
Stimulus generalization by fenfluramine in a quipazine-ketanserin drug discrimination is not dependent on indirect serotonin release.
2002 May
Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial.
2002 May-Jun
Molecular characterisation of antidepressant effects in the mouse brain using gene expression profiling.
2002 May-Jun
Patents

Sample Use Guides

The initial dosage of Tolvon should be judged individually. It is recommended that treatment begins with a daily dose of 30mg given in three divided doses or a single bedtime dose and be adjusted weekly in the light of the clinical response. The effective daily dose for adult patients usually lies between 30mg and 90mg (average 60mg) in divided doses or as a single bedtime dose. A maximum daily dose of 120mg should not be exceeded.
Route of Administration: Oral
Binding of mianserin to 5-HT2A receptor was measured using radioligand binding assay, using [125I]R91150 as a radioligand, and cloned human receptors. pKi for displacement of R91150 was 4.3 nM.
Substance Class Chemical
Created
by admin
on Sat Jun 26 02:34:11 UTC 2021
Edited
by admin
on Sat Jun 26 02:34:11 UTC 2021
Record UNII
250PJI13LM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MIANSERIN
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
DIBENZO(C,F)PYRAZINO(1,2-A)AZEPINE, 1,2,3,4,10,14B-HEXAHYDRO-2-METHYL-
Common Name English
(+/-)-MIANSERIN
Common Name English
MIANSERIN [MI]
Common Name English
MIANSERIN [INN]
Common Name English
1,2,3,4,10,14B-HEXAHYDRO-2-METHYLDIBENZO(C,F)-PYRAZINO(1,2-A)AZEPINE
Common Name English
MIANSERIN [VANDF]
Common Name English
J16.389I
Code English
MIANSERIN [HSDB]
Common Name English
TOLVON
Brand Name English
MIANSERINE
Common Name English
MIANSERIN [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C72900
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
WHO-ATC N06AX03
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
NCI_THESAURUS C265
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
NCI_THESAURUS C66885
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
WHO-VATC QN06AX03
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL6437
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
PRIMARY
DRUG BANK
DB06148
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
PRIMARY
INN
2543
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
PRIMARY
LACTMED
Mianserin
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
PRIMARY
PUBCHEM
4184
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
PRIMARY
RXCUI
6929
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
PRIMARY RxNorm
ECHA (EC/EINECS)
246-088-6
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
PRIMARY
DRUG CENTRAL
1796
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
PRIMARY
MERCK INDEX
M7521
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C87209
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
PRIMARY
MESH
D008803
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
PRIMARY
WIKIPEDIA
MIANSERIN
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
PRIMARY
IUPHAR
135
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
PRIMARY
CAS
24219-97-4
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
PRIMARY
EVMPD
SUB08939MIG
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
PRIMARY
HSDB
7182
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
PRIMARY
FDA UNII
250PJI13LM
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
PRIMARY
EPA CompTox
24219-97-4
Created by admin on Sat Jun 26 02:34:11 UTC 2021 , Edited by admin on Sat Jun 26 02:34:11 UTC 2021
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
METABOLIC ENZYME -> SUBSTRATE
Metabolizing reaction by CYP2D6: O-demethylation
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
Pharmacological action: Tricyclic antidepressant drug (TCA)
TARGET -> AGONIST
SHORT-ACTING
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE ACTIVE -> PARENT
The plasma concentration of the compound was within the predicted therapeutic range in only 43% of patients.
AMOUNT ADMINISTERED
PLASMA
Related Record Type Details
ACTIVE MOIETY